Skip to main content
. 2018 Nov 12;7(11):84. doi: 10.1038/s41389-018-0095-x

Fig. 5. Chromatin switches upon CX-4945 treatment.

Fig. 5

Indicated cell lines and primary cells were treated with 10 μM CX-4945 or with DMSO control and evaluated by qChIP for Ikaros binding (a, b) and the H3K4me3 histone mark (c, d) at the ARID5B promoter in the indicated cells. ***p < 0.001 compared to WT-anti-Ikaros control. Graphed data in ad are the mean+/– SD of triplicates representative of one of 3 independent experiments or 3 patient samples